Related Experiment Videos
Current therapeutic strategies in glomerulonephritis
1Department of Renal Medicine, Singapore General Hospital, Singapore.
Annals of the Academy of Medicine, Singapore
|September 25, 1999
Summary
Glomerulonephritis (GN) treatment has advanced with new drugs like cyclosporine A and tacrolimus for refractory cases. Additional therapies aim to slow progression to end-stage renal disease.
Area of Science:
- Nephrology
- Immunology
Background:
- Glomerulonephritis (GN) treatment has evolved significantly over the past two decades.
- Steroids and cyclophosphamide remain primary treatments, but newer agents offer alternatives for refractory cases.
Purpose of the Study:
- To present a comprehensive therapeutic approach for various forms of primary GN.
- To outline treatment strategies for patients unresponsive to conventional therapies.
Main Methods:
- Review of current therapeutic agents for glomerulonephritis.
- Discussion of novel immunosuppressants and supportive care strategies.
Main Results:
- Cyclosporine A and tacrolimus (FK 506) demonstrate efficacy in achieving remission in steroid- and cyclophosphamide-resistant nephrotic syndrome.
- Supportive therapies including ACE inhibitors, ARBs, dipyridamole, warfarin, protein restriction, and hypercholesterolemia management can retard disease progression.
Conclusions:
- Modern pharmacotherapy offers improved outcomes for glomerulonephritis patients.
- A multi-faceted therapeutic strategy is crucial for managing diverse forms of primary GN and preventing end-stage renal failure.